Anserine

Introduction

Background

Anserine is a naturally occurring dipeptide, a molecule composed of two amino acids, beta-alanine and 1-methylhistidine. It is structurally similar to carnosine but contains a methyl group on the imidazole ring of histidine. Anserine is widely distributed in the muscles of various vertebrates, particularly birds (from which it derives its name,Ansermeaning goose) and fish. Its presence in muscle tissue suggests a role in maintaining muscle function and health.

Biological Basis

The primary biological role of anserine is thought to be as an antioxidant and a buffer against pH changes, especially during intense muscle activity. As an antioxidant, it helps to neutralize reactive oxygen species, protecting cells from oxidative damage. Its buffering capacity contributes to maintaining optimal pH levels in muscle tissue, which is crucial for enzyme function and preventing muscle fatigue. Anserine is synthesized in the body from its constituent amino acids and can also be obtained through the diet, primarily from poultry and fish.

Clinical Relevance

Research into anserine suggests potential health benefits, particularly in relation to oxidative stress and inflammation. Its antioxidant properties may contribute to cellular protection and could have implications for conditions associated with oxidative damage. Some studies explore its potential role in supporting cognitive function and reducing fatigue, although more research is needed to fully understand these effects and their clinical significance.

Social Importance

Anserine has gained attention in the nutritional and supplement industries due to its perceived health benefits. It is sometimes included in dietary supplements marketed for athletes to support muscle recovery and performance, and for individuals seeking general antioxidant support. As a component of common dietary protein sources like chicken and fish, anserine contributes to the nutritional value of these foods and is part of a balanced diet.

Limitations

Methodological and Statistical Constraints

The studies faced several methodological and statistical limitations that could influence the interpretation and reliability of their findings. A moderate sample size in some cohorts limited the statistical power to detect genetic effects of modest magnitude, increasing the susceptibility to false negative findings.^[1] Conversely, the extensive multiple testing inherent in genome-wide association studies (GWAS) introduced a risk of false positive associations, necessitating rigorous replication in independent cohorts to confirm initial discoveries. ^[1] Furthermore, the genotyping arrays used, such as the Affymetrix 100K chip or subsets of HapMap SNPs, offered only partial coverage of genetic variation, potentially missing some genes or variants not tagged by the array, and thus limiting the comprehensive study of candidate genes. ^[2] When imputation was used to infer missing genotypes or compare across studies with different marker sets, there was a risk of imputation errors, which could affect the accuracy of genotype calls. ^[3]

Specific analytical choices also presented limitations. Performing only sex-pooled analyses meant that genetic associations unique to either males or females might have been overlooked. ^[2] While some studies employed methods to account for population stratification, such as family-based tests or genomic control, an analytical approach considering all observed or estimated genotypes might still not be entirely immune to subtle effects of population structure. ^[4]Moreover, focusing exclusively on multivariable models, while important for controlling confounders, potentially led to missing significant bivariate associations between single nucleotide polymorphisms (SNPs) and phenotypes.^[5] The observed replication gaps, where only a fraction of previously reported associations were confirmed, highlight the combined challenges of statistical power, potential false positives in initial reports, and differences in study cohorts. ^[1]

Generalizability and Phenotype Characterization

The generalizability of the findings is limited by the demographic characteristics of the study populations. Many cohorts were predominantly composed of individuals of white European descent, often middle-aged to elderly. ^[1] This demographic homogeneity means that the results may not be directly applicable or generalizable to younger populations or individuals of other ethnic or racial backgrounds. ^[1] Additionally, some studies collected DNA at later examinations, which could introduce a survival bias, as only individuals who survived to those examination points were included. ^[1]

Challenges in phenotype characterization also impact the studies. For instance, averaging echocardiographic traits over periods as long as twenty years, during which different equipment might have been used, could introduce misclassification and dilute true associations. ^[6] Such averaging also assumes a consistency of genetic and environmental influences across a wide age range, an assumption that might mask age-dependent genetic effects. ^[6]Some studies relied on proxy measures for phenotypes, such as using TSH as an indicator of thyroid function due to the absence of free thyroxine measurements, which might not fully capture the underlying biological process.^[5]Furthermore, certain biomarkers, like cystatin C, may reflect broader cardiovascular disease risk in addition to kidney function, complicating the interpretation of their associations.^[5] The inability to assess previously reported non-SNP variants, such as the UGT1A1 repeat, due to the lack of coverage on SNP arrays, means that potentially important genetic influences were not evaluated. ^[1]

Environmental and Contextual Confounders

The studies did not extensively investigate the role of environmental factors or gene-environment interactions, which are known to modulate genetic effects. Genetic variants can influence phenotypes in a context-specific manner, with their effects being modified by environmental influences. ^[6]The absence of such investigations means that the full spectrum of how genes interact with lifestyle, diet, or other environmental exposures to affect traits remains unexplored.^[6] This limitation is significant because environmental factors can considerably influence phenotypic expression, and their omission may lead to an incomplete understanding of the genetic architecture of complex traits. The assumption that similar genes and environmental factors influence traits uniformly across a wide age range may not hold true, potentially obscuring age-dependent genetic effects. ^[6]

Variants

Genetic variations play a significant role in influencing various metabolic pathways and physiological traits, which can indirectly or directly impact the levels and function of anserine. Anserine, a dipeptide found abundantly in muscle and brain tissue, is known for its antioxidant, antiglycation, and pH-buffering properties. Variants in genes involved in lipid metabolism, uric acid transport, and energy homeostasis can alter the broader metabolic environment, thereby affecting anserine’s synthesis, degradation, or its protective demand.

Variants near the BCL11A gene, such as *rs11886868 * and *rs10837540 *, have been identified as strong association signals for persistent fetal hemoglobin (HbF) levels.^[4] The BCL11Agene encodes a zinc-finger protein that acts as a transcriptional repressor, playing a key role in the developmental silencing of fetal hemoglobin expression. Higher HbF levels are beneficial in certain hemoglobinopathies like beta-thalassemia, improving oxygen transport efficiency.^[4]While not directly linked to anserine, systemic physiological parameters such as oxygenation and overall metabolic health, influenced by hemoglobin function, can impact muscle integrity and cellular stress, thereby potentially affecting the demand for and availability of anserine as a cellular protectant.

The SLC2A9gene is critical for the regulation of uric acid levels, encoding a newly identified transporter that significantly influences serum urate concentration and excretion.^[7] Variants in SLC2A9can therefore impact an individual’s risk for conditions like gout, which is characterized by elevated uric acid. Like anserine, uric acid is a potent antioxidant, and both molecules contribute to the body’s overall antioxidant defense system. Disruptions in urate metabolism, due toSLC2A9variants, may reflect or contribute to a broader imbalance in oxidative stress or metabolic health that could also influence the physiological roles and demand for anserine.

Genes involved in lipid metabolism, such as HMGCR, MLXIPL, and FADS1, also exhibit variants with metabolic implications. Common single nucleotide polymorphisms (SNPs) inHMGCR, which encodes the rate-limiting enzyme in cholesterol synthesis, are associated with low-density lipoprotein (LDL) cholesterol levels.^[8] Similarly, variations in MLXIPL, a transcription factor that regulates glucose-responsive gene expression and fat synthesis, are linked to plasma triglyceride levels.^[9] The FADS1 gene, encoding fatty acid desaturase 1, is involved in the synthesis of crucial polyunsaturated fatty acids, and its genotype influences the efficiency of the delta-5 desaturase reaction, affecting concentrations of various phospholipids and sphingomyelins. ^[10]Given anserine’s role in muscle metabolism and its antioxidant capacity against lipid peroxidation, genetic predispositions to altered lipid profiles or fatty acid metabolism could indirectly affect anserine’s protective functions and its overall homeostatic balance within tissues.

Furthermore, genetic variations near the MC4Rgene are associated with traits like waist circumference and insulin resistance.^[11] The MC4Rgene encodes the melanocortin 4 receptor, a key regulator of energy balance, appetite, and body weight in the brain. Variants inMC4Rcan predispose individuals to obesity and metabolic syndrome, conditions characterized by chronic metabolic dysregulation. In such states of increased metabolic stress and inflammation, the protective roles of compounds like anserine, through its antioxidant and antiglycation activities, may become particularly important. Therefore, genetic influences on energy homeostasis and body composition could indirectly modulate the physiological demand for and the protective benefits derived from anserine.

Key Variants

RS ID	Gene	Related Traits
chr12:116564853	N/A	anserine measurement

Biological Background

Genetic Basis of Metabolic and Cardiovascular Traits

The genetic architecture underlying complex human traits, including metabolic and cardiovascular health, involves numerous loci that contribute to phenotypic variation. Genome-wide association studies (GWAS) have identified specific genetic variants, such as single nucleotide polymorphisms (SNPs), that are associated with various physiological measures and disease risks^{[1], [3], [4], [6], [7], [9], [10], [12], [13], [14], [15], [16]}. ^[11] For instance, variants in genes like MLXIPLhave been linked to plasma triglyceride levels, indicating a role in lipid metabolism regulation.^[9] Similarly, common genetic variation near MC4Rinfluences waist circumference and insulin resistance, highlighting the genetic contribution to obesity-related metabolic traits.^[11]

These genetic influences extend beyond common metabolic parameters to include more specific cellular and physiological functions. For example, the gene BCL11Ais associated with persistent fetal hemoglobin production, a mechanism relevant to ameliorating the phenotype of beta-thalassemia.^[4] Another critical gene, SLC2A9, functions as a urate transporter, with its genetic variations significantly impacting serum urate concentration, urinary urate excretion, and the risk of gout, sometimes with pronounced sex-specific effects^[7]. ^[17] The identification of protein quantitative trait loci (pQTLs) further demonstrates that genetic variants can influence the abundance of specific proteins, thereby modulating various biological pathways and phenotypes. ^[14]

Molecular and Cellular Mechanisms in Homeostasis

Maintaining physiological homeostasis relies on intricate molecular and cellular pathways that regulate metabolism and cellular function. Lipid metabolism, for instance, involves complex processes governing the synthesis, transport, and breakdown of triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), all of which are critical for energy storage and cell membrane integrity^[12]. ^[3]Key biomolecules such as enzymes facilitate these metabolic reactions, while receptors mediate cellular uptake and signaling, and hormones like insulin regulate glucose homeostasis^[13]. ^[11] Transcription factors, such as MLXIPL, play a crucial role by controlling the expression of genes involved in these metabolic pathways, thereby influencing systemic lipid levels. ^[9]

Beyond lipid and glucose regulation, other metabolic pathways are equally vital. Uric acid metabolism, for example, is tightly controlled by transporters likeSLC2A9, which regulates the balance of urate in the blood and its excretion by the kidneys^[7]. ^[17]Disruptions in these molecular transport mechanisms can lead to hyperuricemia and conditions like gout. Cellular functions also encompass the production of specialized cells, such as F cells responsible for fetal hemoglobin, a process influenced by genetic factors including a zinc-finger protein encoded on chromosome 2p15.^[15] These interconnected molecular and cellular mechanisms collectively ensure the proper functioning of various physiological systems.

Pathophysiology of Systemic Disease

Disruptions in metabolic and cellular homeostasis can lead to a range of pathophysiological processes that manifest as systemic diseases, particularly affecting the cardiovascular system. Subclinical atherosclerosis, characterized by the accumulation of plaque in arterial territories, represents an early stage of cardiovascular disease and is influenced by genetic factors.^[16]Endothelial dysfunction, where the inner lining of blood vessels loses its ability to regulate vascular tone and prevent clot formation, is another key pathological process contributing to cardiovascular morbidity.^[6]These processes can lead to structural changes in organs, such as alterations in echocardiographic dimensions of the heart, reflecting the heart’s response to chronic stress or disease.^[6]

Metabolic dysregulation, including dyslipidemia (abnormal lipid levels) and insulin resistance, serves as a significant driver for these cardiovascular pathologies^{[12], [13]}. ^[11]When homeostatic mechanisms fail, compensatory responses may occur, but often these are insufficient to prevent disease progression. For instance, chronic hyperuricemia due to impaired urate transport can lead to the deposition of urate crystals, causing gout and contributing to broader metabolic syndrome components^[7]. ^[17]The interplay of genetic predispositions and environmental factors ultimately determines the onset and severity of these complex disease mechanisms, impacting overall systemic health.

Interconnected Biomarker Profiles and Disease Risk

The human body’s physiological state can be comprehensively assessed through metabolomics, which measures endogenous metabolites in bodily fluids, providing a functional readout of metabolic health. ^[10] Genetic variants that influence the homeostasis of key lipids, carbohydrates, and amino acids are often associated with specific biomarker traits, which serve as intermediate phenotypes on a continuous scale ^[1]. ^[10]These metabolite profiles are not isolated; they are interconnected, with alterations in one pathway often impacting others, such as the relationship between triglyceride levels and overall lipid concentrations^{[9], [12]}. ^[3]

Systemic consequences of dysregulation are evident in conditions like polygenic dyslipidemia, where multiple genetic loci collectively contribute to abnormal lipid concentrations, increasing the risk of coronary artery disease^[12]. ^[3]Similarly, the association of genetic variants with diabetes-related traits and insulin resistance highlights how specific biomarker changes, like waist circumference, reflect underlying metabolic dysfunction and increased disease susceptibility^[13]. ^[11] By studying these integrated biomarker profiles and their genetic determinants, researchers can gain deeper insights into affected pathways and the complex etiology of common chronic diseases. ^[10]

There is no information about ‘anserine’ in the provided context.

References

[1] Benjamin EJ et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, 2007.

[2] Yang, Qiong, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, no. 1, 2007, p. 56.

[3] Willer CJ et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, 2008.

[4] Uda M et al. “Genome-wide association study shows BCL11Aassociated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia.”Proc Natl Acad Sci U S A, 2008.

[5] Hwang, Shih-Jen, et al. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Medical Genetics, vol. 8, no. 1, 2007, p. 58.

[6] Vasan RS et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, 2007.

[7] Vitart V et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, 2008.

[8] Burkhardt, R. et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, vol. 28, no. 11, 2008, pp. 2090-2096.

[9] Kooner JS et al. “Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.” Nat Genet, 2008.

[10] Gieger C et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, 2008.

[11] Chambers JC et al. “Common genetic variation near MC4Ris associated with waist circumference and insulin resistance.”Nat Genet, 2008.

[12] Kathiresan S et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, 2008.

[13] Meigs JB et al. “Genome-wide association with diabetes-related traits in the Framingham Heart Study.” BMC Med Genet, 2007.

[14] Melzer D et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, 2008.

[15] Menzel S et al. “A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15.” Nat Genet, 2007.

[16] O’Donnell CJ et al. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Med Genet, 2007.

[17] Doring A et al. “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.”Nat Genet, 2008.